Answers are grounded in this paper and cite their sources.
This article refers to ‘Sodium–glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction’ by S.R. Yurista et al., published in this issue on pages 862–873. Sodium–glucose co-transporter 2 (SGLT2) inhibitors (i.e. empagliflozin, canagliflozin and dapagliflozin) are a novel class of anti-hyperglycaemic agents that have entered the spotlight of scientific interest after completion of the three landmark cardiovascular outcome trials (i.e. EMPA-REG OUTCOME with empagliflozin,1 CANVAS Program with canagliflozin,2 and DECLARE-TIMI 58 with dapagliflozin3). These trials have highlighted substantial cardiovascular benefits in patients with type 2 diabetes and high cardiovascular risk. Importantly, they have suggested that lowering the risk of heart failure hospitalisation may be the most relevant outcome of treatment with SGLT2 inhibitors and a major driver of their salutary cardiovascular effects. Indeed, this effect was firstly observed with empagliflozin, which reduced heart failure hospitalisation by 35% among patients with type 2 diabetes and established cardiovascular disease.1 A similar risk reduction was subsequently observed with canagliflozin and dapagliflozin (by 33% and 27%, respectively) in trials including patients with established atherosclerotic disease as well as those with multiple risk factors.2, 3 A recent meta-analysis of these three trials has confirmed that SGLT2 inhibitors consistently reduce the risk of heart failure hospitalisation to a similar magnitude across the spectrum of baseline atherosclerotic risk or a history of heart failure.4 Despite these remarkable results, the mechanisms of cardiovascular benefits with SGLT2 inhibitors have not yet been elucidated. A recent mediation analysis of the EMPA-REG OUTCOME has shown that improvement of glycaemic control had a modest effect on cardiovascular benefits of empagliflozin, while changes in traditional risk factors (e.g. blood pressure, serum lipids) and parameters of renal function, had no impact at all.5 Hence, mechanisms beyond glycaemic control have been proposed.6 If confirmed, these pleiotropic effects of SGLT2 inhibition may have profound implications beyond therapy of diabetes, that may include prevention of heart failure in patients without diabetes, as well as treatment of heart failure in people with or without type 2 diabetes. However, at this point, there is insufficient data from human studies to support this hypothesis, which is being explored in several ongoing clinical trials with empagliflozin (e.g. EMPEROR-Reduced, NCT03057977, and EMPEROR-Preserved, NCT03057951) and dapagliflozin (e.g. DAPA-HF, NCT03036124, and PRESERVED-HF, NCT03030235).7, 8 Awaiting the results of human studies, in this issue of the Journal, Yurista et al.9 sought to provide translational data on cardiac effects of empagliflozin in a non-diabetic rodent model of post-myocardial left ventricular dysfunction. In this complex and meticulously conducted experimental study, 140 non-diabetic rats were randomised to myocardial infarction by ligation of the left anterior descending artery, or sham surgery. Rats were also randomised to receive empagliflozin or vehicle (control), either 2 days before surgery (early treatment) or 2 weeks after the procedure (late treatment). Echocardiography was used to assess longitudinal changes in left ventricular ejection function after surgery. Following 10 weeks of treatment, anesthetised rats were sacrificed, and the hearts were excised for further pathological and molecular analyses. The results provide important insights into the mechanisms by which empagliflozin may intersect with pathological processes responsible for the development of heart failure after myocardial infarction in non-diabetic milieu. Empagliflozin produced a marked increase in diuresis, without causing changes in blood pressure, hypoglycaemia, or disturbances in serum electrolytes and kidney function. Although the size of myocardial infarction was similar between rats receiving empagliflozin and the controls, the drug attenuated deterioration in left ventricular ejection fraction in both early and late treatment groups compared with controls. This was subtended by less adverse cardiac remodelling in terms of myocyte hypertrophy and cardiac fibrosis. In addition, empagliflozin suppressed cardiac oxidative stress in both early and late treatment groups. Likewise, it had a favourable effect on cardiac mitochondrial content and energy production. It also stimulated restoration of cardiac glucose and fatty acid oxidation, which are often profoundly impaired in the failing heart. Furthermore, empagliflozin increased plasma ketone body concentration and cardiac expression of the three key proteins involved in their utilisation. This suggests that empagliflozin might boost myocardial capacity to utilise ketone bodies as a highly efficient metabolic substrate in the setting of heart failure. However, increased ketolysis per se could not be confirmed. Tentative interpretation of the present study by Yurista et al.9 may indicate potential mechanisms resulting in cardiovascular benefits of SGLT2 inhibitors in humans, independently of diabetes. The translational aspects of these findings are in line with a hypothesis that SGLT2 inhibitors improve haemodynamics by enhancing osmotic diuresis and natriuresis that lead to vascular decongestion and reduction in preload.10 Notably, these effects can occur in patients without diabetes and appear to be maintained over time.11, 12 Furthermore, it has been suggested that osmotic diuresis induced by SGLT2 inhibition may result in greater electrolyte-free water excretion and greater fluid clearance from the interstitial compartment compared to circulation.13 This effect may decrease volume overload in heart failure without causing excessive neurohormonal activation, electrolyte imbalance or organ hypoperfusion, commonly observed with conventional diuretics.13 The analysis by Yurista et al.9 supports this concept by showing markedly increased diuresis with preserved blood pressure, serum electrolyte concentration and kidney function in the non-diabetic setting. Potential translation of these findings can be observed in clinical trials in patients with type 2 diabetes, which demonstrated early separation of heart failure outcome curves with SGLT2 inhibitors compared with placebo. Further support comes from the mediation analysis of EMPA-REG OUTCOME showing that an increase in haematocrit, presumably due to vascular decongestion, was by far the most significant contributor (∼50%) to the improvement in outcomes with empagliflozin.5 Also, a recent subanalysis of the same trial has suggested that empagliflozin can ameliorate manifestations of heart failure by reducing signs of congestion as well as a requirement for diuretics.14 Although the present study did not show reduction in the size of myocardial infarction with empagliflozin, there was a substantial preservation of left ventricular ejection fraction following myocardial infraction, observed with either early or late drug administration. These effects may relate to attenuation of myocardial hypertrophy and interstitial fibrosis and reduction in indices of oxidative stress with empagliflozin. This is in line with other experimental data suggesting significant antifibrotic effects of SGLT2 inhibitors in the myocardium, independently of diabetes.15, 16 Further support for this concept has come from isolated human myocyte experiments demonstrating improvement in diastolic stiffness with empagliflozin, irrespective of diabetes.16 Similar to experimental findings, the EMPA-HEART Cardiolink-6 study has recently demonstrated that empagliflozin could produce early reverse cardiac remodelling in patients with type 2 diabetes and stable coronary artery disease.17 Whether patients with an acute or recent myocardial infraction could derive similar benefits is currently unknown. A subanalysis of DECLARE-TIMI 58 provides an insight into this issue by demonstrating greater benefits on outcomes with dapagliflozin among individuals with prior myocardial infarction compared to those with stable coronary artery disease or atherosclerotic risk factors.18 However, this concept merits further investigation. The study by Yurista et al.9 has also sought to provide evidence of a favourable effect of empagliflozin on mitochondrial function and metabolism, which could add to the improvement in myocardial contractility. The results have shown enlargement in mitochondrial content and energy production, coupled with down-regulation of proteins involved in glucose and fatty acid uptake and up-regulation of proteins responsible for ketone body utilisation. These alterations are consistent with the ‘ketone body hypothesis’ postulating that SGLT2 inhibitors can produce a shift towards more efficient substrate for energy generation.6 In conjunction with positive haemodynamic impact and greater oxygen delivery due to higher haematocrit, the increase in cardiac energy production may lead to improvement in contractility. However, whether this shift in energy metabolism actually occurs in humans remains to be seen. In conclusion, the present study has demonstrated a beneficial impact of empagliflozin on post-infarction myocardial remodelling and function in non-diabetic rats, associated with substantial improvement in cardiac metabolism. Although promising, these results should be interpreted cautiously because rodent models may significantly differ from human pathophysiology, and therefore translation into clinical medicine may be misleading. Further mechanistic studies in humans are needed to improve understanding of the existing clinical data, and to specify mechanisms underlying beneficial cardiovascular effects of SGLT2 inhibitors. Ongoing and upcoming trials will better define the therapeutic scope of these medications, but there is little doubt that SGLT2 inhibitors will have a prominent role in cardiovascular medicine. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Seferović et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: